Please assess the completion status of the following clinical trial:

Trial Title: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed mantle cell or follicular lymphoma~* Relapsed or refractory disease~* ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, 2 or 3~Exclusion Criteria:~* Pre-existing sensory or motor peripheral neuropathy~* No active or untreated CNS (Central Nervous System) lymphoma~* History of severe, life-threatening hypersensitivity or infusion reactions prior rituximab treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velcade and Rituximab (Type: EXPERIMENTAL): Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14

Based on this trial design, predict the completion outcome and termination type (if applicable).